author-photo

Leisha A. Emens

Johns Hopkins University
Johns Hopkins University School of Medicine

151

Papers

8856

Citations

Citation Trend

Filter By

Papers (102) Sort By

Journal Conference Others

127TiP Phase II, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine (CX 2009) in metastatic HR-positive/HER2 non-amplified breast cancer (mHR+/HER2− BC) and CX-2009 as monotherapy and in combination with pacmilimab in metastatic triple-negative breast cancer (mTNBC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
329TiP KATE3: A phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
QSPIO-TNBC: A Quantitative Systems Pharmacology Platform in Immune-Oncology for Triple-Negative Breast Cancer

2021
Show All
- Source
- Cite
- Save
Citations (0)
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy).

2021 Journal of Translational Medicine
Show All
- Source
- Cite
- Save
Citations (1)
Abstract PS9-15: Utilizing education to strengthen oncologist' understanding of immunotherapy in triple negative breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD14-05: Genomic profiling and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS1-10: Outcomes after sentinel lymph node biopsy and radiation therapy in women over 70 years old with ER+, HER2-, clinically node negative breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

2020 BMJ
Show All
- Source
- Cite
- Save
Citations (1)